Abdomen, and thorax, radiographic appearance of, effect of pharmaceuticals on, 349-377
Abdominal cavity, feline, in cardiac disease, noncardiac changes in, 409
Acromegaly, from therapy with progestagens, 366-367
Anesthesia, general, hypostatic congestion of lungs following, 369-370 influencing heart rate, 372-373
Anorexia, persistent, barium-impregnated polyethylene spheres for investigation of, 463
Anti-inflammatory drugs, nonsteroidal, and gastrointestinal ulceration, 354-356
Antineoplastic agents, causing pulmonary toxicity, 370
Arthropathies, infective, in cats, 299-300
Aspergillosis, disseminated, 341
Atrium, left, enlargement of, in feline cardiac disease, 416-417
Bone, benign changes of, 342-345
cortex of, evaluation of, in bone disease, 319-321, 328
infection of. See Osteomyelitis.
lesions of, assessment of rate of change of, in bone disease, 322
optimization of radiographic quality in, 316-317
periosteal changes in, in bone disease, 317-319, 320, 321, 324, 326, 327
periostitis, 327
periosteal thickening, 327
periosteitis, 327
radiography of, and additional assessments, in diagnosis of disease, 315-316
remodeling and resorption of, 315
serial radiographic studies of, in bone disease, 324, 328-329
Bone biopsy, in bone disease, 329
Bloating, chronic or recurrent, barium-impregnated polyethylene spheres for investigation of, 463
Blastomycosis osteomyelitis, 340
Blastomyces osteomyelitis, 340
Bone biopsy, in bone disease, 329
Bone cysts, 342-344

Bacterial osteomyelitis, 320, 325, 336-338
Barium-impregnated polyethylene spheres, and other modalities, compared, to determine gastrointestinal motility, 464
calculation of gastric emptying rate of, 454
calculation of orocolic transit rate of, 454
capsules containing, 449, 451
dose of, 450
in acute presentations, 460-462
in chronic presentations, 462-464
in gastrointestinal disease, pros and cons of, 449-465
indications for use of, 460-464
methods of administration of, 451-452
principles of use of, 449-450
radiography of, patterns in, 454-460
restraint for, 453
timing of, 453
views of, 453
radiopaque marker studies of, interpretation of, 454-460
studies of, on empty stomach, 452
studies with Prescription Diet d/d, 452
studies with Prescription Diet r/d, 452-453
Bladder, pelvic, incontinence in, 435-436
Bloating, chronic or recurrent, barium-impregnated polyethylene spheres for investigation of, 463
Bone, benign changes of, 342-345
cortex of, evaluation of, in bone disease, 319-321, 328
infection of. See Osteomyelitis.
lesions of, assessment of rate of change of, in bone disease, 322
optimization of radiographic quality in, 316-317
periosteal changes in, in bone disease, 317-319, 320, 321, 324, 326, 327
periostitis, 327
periosteal thickening, 327
periosteitis, 327
radiography of, and additional assessments, in diagnosis of disease, 315-316
remodeling and resorption of, 315
serial radiographic studies of, in bone disease, 324, 328-329
Bone biopsy, in bone disease, 329
Boning cysts, 342-344
Bone disease, assessment of rate of change of lesions in, 322
bone biopsy in, 329
evaluation of bone cortex in, 319–321, 328
evaluation of margins of lesions in, 321–322
evaluation of medullary cavity of bone in, 319, 321, 328
malignant, 322–335
malignant versus nonmalignant, 315–347
margination of bone in, 319, 324
periosteal changes in bone in, 317–319, 320, 321, 324, 326, 327
radiographic characterization of, 317–322
radiography and additional assessments in diagnosis of, 315–316
Bone infarcts, in bone disease, 322, 327
Bowel obstruction, caused by radiolucent body, barium-impregnated polyethylene spheres to rule out, 461
partial, barium-impregnated polyethylene spheres for screening in, 462
Brain, anatomy of, 304–307

Calculi, cystic, incontinence in, 436, 440
Cardiac disease(s), feline, acquired, radiographic findings in, 421–423
clinical signs of, 395–396
congenital, radiographic findings in, 423–424
left atrial enlargement in, 416–417
of left heart, 416
radiographic patterns of, cardiac changes in, 411–420
noncardiac changes in, 405–411
radiography of, 395–425
advantages of, 396
indications for, 395–396
risk-benefit assessment of, 396–397
technique of, 397–399, 400–403
right atrial enlargement in, 419
right ventricular enlargement in, 419, 420
Cardiomegaly, feline, radiography in, 415, 416
hyperthyroid, feline, 421
Cardiomyopathy, dilated, feline, 416, 421
hypertrophic, feline, 412, 414, 416, 421
unclassified (restrictive), feline, 412, 416, 418, 421
Cardiopulmonary system, normal radiographic, in cats, 399–405
Cartilaginous exostosis, multiple, 342, 343
Cats, and dogs, urinary incontinence and abnormal urination in, diagnosis of, 427–448
cardiac disease in. See Cardiac disease(s), feline.
cardiopulmonary anatomy of, normal radiographic, 399–405
joint diseases in. See Joint diseases, feline.
Central canal, opacification of, 312, 313
Chemotherapy, complications of, affecting urinary tract, 368
Chondrosarcoma, 330–331
Cisapride, and acceleration of gastric emptying, 356–357
Codman’s triangle of new bone, 318, 321, 324, 327
Colon, dilatation of, motility in colon and rectum in, 363
Computed tomography, of lateral epicondylar osteophytes, in elbow dysplasia in dogs, 264
Constipation, chronic, barium-impregnated polyethylene spheres for investigation of, 463–464
Coronoid process, fragmentation of, in canine elbow dysplasia, 257–258
radiography in, 257–258
medial, of ulna, 261, 262
Corticosteroid therapy, causing pulmonary complications, 370–371
Cushing’s syndrome, iatrogenic, following corticosteroid therapy, 366
Cyclophosphamide, effects of, on urinary tract, 368
Cystitis, following acroelin therapy, 368
Cysts, bone, 342–344
Dexamethasone, and gastrointestinal ulceration, 356
Diaphragmatic hernia, peritoneopericardial, feline, 409, 423
Diarrhea, chronic, barium-impregnated polyethylene spheres for screening in, 462–463
Diskospondylitis, incontinence in, 443, 445
Dogs, and cats, urinary incontinence and abnormal urination in, diagnosis of, 427–448
elbow dysplasia in. See Elbow dysplasia, canine.
hip dysplasia in. See Hip dysplasia, in young dog.
Drug(s). See also Pharmaceuticals.
Dura mater, spinal, 305–307
Dural drape sign, 311

Elbow, bones of, evaluation of, 258, 259
incongruity and subluxation of, 258–259, 260
normal, 259
Elbow dysplasia, canine, 257–266
fragmentation of coronoid process in, 257–258
lateral epicondylar osteophytes in, 262, 263
computed tomography images of, 264
periarticular osteophytes in, 260–261
subtrochlear sclerosis in, 261, 263
Epicondylar osteophytes, lateral, in elbow dysplasia in dogs, 264
Epidural space, opacification of, 309–310, 311
Epidurograms, lateral cervicothoracic and thoracolumbar, of dog, 310, 311
Erythromycin, gastric emptying and, 357
Esophagus, radiographic appearance of, medications and, 364, 365
Fibrosarcoma, 331–332
Foreign bodies, linear, barium-impregnated polyethylene spheres to rule out, 462
Fungal osteomyelitis, 325, 339–342
Gastric emptying, pharmaceuticals delaying, 352
Gastric transit, pharmaceuticals accelerating, radiography and, 356–358
Gastric ulcers, pharmaceuticals inducing, radiography and, 354–356
Gastrointestinal disease, barium-impregnated polyethylene spheres in, pros and cons of, 449–465
Gastrointestinal motility, determination of, barium-impregnated polyethylene spheres and other modalities in, compared, 464
Gastrointestinal system, radiographic appearance of, medications and, 350–354, 364
radiopacity of, oral pharmaceuticals increasing, 358–363
Heart, chemotherapeutic agents adversely affecting, 373
dimensions and function of, anesthesia influencing, 372
malposition of, causes of, 372
size of, in lateral radiographs, results of study of, 384–386
in radiographs, case material to study, 380
vertebral scale system to measure, 379–393
discussion of, 388–392
in ventrodorsal and dorsoventral radiographs, study of, 386–387
measurement of, methods of, 380–384
vertebral heart size measurement method in, 380, 381
radiographic assessment of, in feline heart disease, 415
Heart disease. See Cardiac disease(s).
Heart rate, anesthesia influencing, 372–373
Heartworm disease, feline, 422
Hemangiosarcoma, 331–332, 333
Hepatomegaly, causes of, 366
radiographic characterization of, 366
Hepatozoonosis, sporotrix, 318, 342
Hip, joints of, in cats, 282, 284
Hip dysplasia, in cats, 282–285, 286
in young dog, assessment of, distraction index of, PennHip method of, 268, 272
future strategies and, 278–279
incidence of, progress in reducing, 274–279
radiographic diagnosis of, 267–280
screening for, methods acceptable for, 273
screening methods for, at different ages, 273
standard extended hip radiographic view of, 269–271
subjective radiographic assessment for, 270, 271
registry reporting, 270, 272
Hyperostosis, 344–345
Hypertension, feline, 422
Hypervitaminosis A, in cats, 293–296
Incontinence, urinary. See Urinary incontinence.
Intestine, large, radiography of, pharmaceuticals influencing, 363–364
small, radiography of, pharmaceuticals influencing, 363
Joints, diseases of, in cats, radiographic features of, 281–302
hip, in cats, 282, 284
Kidneys, disorders of, induced by drug therapy, 368
Large intestine, radiography of, pharmaceuticals influencing, 363–364
Liver, blood supply to, 365
drugs influencing, 365–366
Lungs, antineoplastic agents causing
toxicity of, 370
corticosteroid therapy causing complica-
tions in, 370–371
hypostatic congestion of, following gen-
eral anesthesia, 369–370

Meninges, 304
Metoclopramide, actions of, 357
Motility disorders, barium-impregnated
polyethylene spheres for screening in,
462–463
Mucopolysaccharidosis, in cats, 291–292,
293, 294
Multioystotic primary neoplasia, 334–335,
336
Musculoskeletal system, feline, in cardiac
disease, noncardiac changes in, 405
Myelograms, cervical, lateral and
ventrodorsal, of dog, 310
lumbar, lateral and ventrodorsal, of cat,
308, 309
Myelographic artifacts, 303–314
Myelography, 303
column of contrast matter in, 307–308

Neoplasia, metastatic, to bone, 332–334,
335
multioystotic primary, 334–335, 336
Nizatidine, and acceleration of gastric
emptying, 358
Nonsteroidal anti-inflammatory drugs, and
gastrointestinal ulceration, 354–356

Orthopedic Foundation for Animals, 267,
268, 271
subjective scoring scheme of, 272, 273
Osteoarthritis, in cats, 281–282, 283
Osteoarthropathy, pulmonary
hypertrophic, 344–345
Osteochondrodysplasia, Scottish fold,
288–291
Osteochondromatosis, synovial, in cats,
285–288
Osteochondrosarcoma, multilobular, 331
Osteomyelitis, bacterial, 320, 325, 336–338
blastomycosis, 340
causes of, 320, 335–336, 337
fungal, 325, 339–342
hematogenous, 338–339
protozoal, 342

Osteopathy, hypertrophic, 344–345
Osteophytes, epicondylar, lateral, in elbow
dysplasia, 264
periarticular, in elbow dysplasia in dogs,
260–261
Osteosarcoma, parosteal, 330
radiographic features of, 327–330
signs and symptoms of, 322–327
sites of, 319, 321, 322–327

Pancreatitis, abdominal radiographic
changes in, 368
associated with drug administration,
367–368
Patent ductus arteriosus, feline, 423
Pelvic bladder, incontinence in, 435–436
Pelvic masses, incontinence in, 439–442
Pericardial disease, feline, 422–423
Peritoneopericardial diaphragmatic hernia,
feline, 409, 423
Pharmaceuticals, delaying gastric
emptying, 352
effect of, on radiographic appearance of
abdomen and thorax, 349–377
Pleurial space, feline, in cardiac disease,
noncardiac changes in, 409–410
Polyarthropathy(ies), immune-mediated,
feline, 297, 298
noninfectious, in cats, 296–299
Polyethylene spheres, barium-
impregnated. See Barium-impregnated
polyethylene spheres.
Prednisone, and gastrointestinal ulceration,
356
Progestagens, acromegaly from therapy
with, 366–367
Prokinetic drug therapy, gastric emptying
and, 356–358
Prostatic disease, incontinence in, 442–443
Protozoal osteomyelitis, 342

Radiographs, of abdomen and thorax,
appearance of, effect of
pharmaceuticals on, 349–377
Radiology, clinical, 257–465
Ranitidine, in inhibition of gastric acid
secretion, 357–358
Respiratory system, feline, in cardiac
disease, noncardiac changes in,
410–414
Right ventricular dysplasia, feline, 422

Sedatives, for chemical restraint,
radiographic appearance of stomach
and, 350–352
Small intestine, bacterial overgrowth in, barium-impregnated polyethylene spheres for investigation of, 463 radiography of, pharmaceuticals influencing, 363
Spinal cord, anatomy of, 304–307 cranial aspect of, 306
Spinal cord parenchyma, opacification of, 312–314
Spleen, masses of, pharmaceuticals and, 364
Splenomegaly, congestive, 364–365 diffuse, pharmaceuticals and, 364
Spondylitis, reactive, 333–335
Sporothrix hepatozoonosis, 318, 342
Stomach, radiographic appearance of, in use of sedatives for chemical restraint, 350–352
Subarachnoid space, opacification of, 308
Subdural space, opacification of, 311–312
Subtrochlear sclerosis, in elbow dysplasia in dogs, 261, 263
Synovial osteochondromatosis, in cats, 285–288

Thorax, abdomen and, radiographic appearance of, effect of pharmaceuticals on, 349–377 depth:width ratios of, assessment of, 384

Ulcration, gastric, pharmaceuticals inducing, radiography and, 354–356
Ulna, medial coronoid process of, 261, 262
Ureteral insertion ectopia, diagnostic evaluation in, 428–434
Urinary tract, complications of chemotherapy affecting, 368
Urination, abnormal, and urinary incontinence, in dogs and cats, diagnosis of, 427–448 diagnostic evaluation in, 427–428
Urogenital system, drugs adversely influencing, 368

Ventricle, left, enlargement of, in feline cardiac disease, 417–419 right, enlargement of, in feline cardiac disease, 419, 420
Ventricular dysplasia, right, feline, 422
Ventricular septal defect, feline, 423
Vomiting, acute, in stable patient, barium-impregnated polyethylene spheres in, 461 chronic, barium-impregnated polyethylene spheres for screening in, 462–463